NZ332426A - Method of treating diseases involving dysfunction of ciliary movement such as ciliary dyskinesia and infertility with uridine triphosphates (UTP) and related compounds - Google Patents

Method of treating diseases involving dysfunction of ciliary movement such as ciliary dyskinesia and infertility with uridine triphosphates (UTP) and related compounds

Info

Publication number
NZ332426A
NZ332426A NZ332426A NZ33242697A NZ332426A NZ 332426 A NZ332426 A NZ 332426A NZ 332426 A NZ332426 A NZ 332426A NZ 33242697 A NZ33242697 A NZ 33242697A NZ 332426 A NZ332426 A NZ 332426A
Authority
NZ
New Zealand
Prior art keywords
ciliary
infertility
utp
related compounds
treating diseases
Prior art date
Application number
NZ332426A
Other languages
English (en)
Inventor
Karla M Jacobus
Ben R Yerxa
William Pendergast
Richard C Boucher
Janet L Rideout
David J Drutz
Michael K James
Monroe Jackson Stutts
Cara A Geary
Eduardo R Lazarowski
Original Assignee
Univ North Carolina
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina, Inspire Pharmaceuticals Inc filed Critical Univ North Carolina
Publication of NZ332426A publication Critical patent/NZ332426A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • External Artificial Organs (AREA)
NZ332426A 1996-03-27 1997-03-27 Method of treating diseases involving dysfunction of ciliary movement such as ciliary dyskinesia and infertility with uridine triphosphates (UTP) and related compounds NZ332426A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62491496A 1996-03-27 1996-03-27
PCT/US1997/005101 WO1997035591A2 (en) 1996-03-27 1997-03-27 Method of treating ciliary dyskinesia with uridine triphosphates and related compounds

Publications (1)

Publication Number Publication Date
NZ332426A true NZ332426A (en) 2000-09-29

Family

ID=24503854

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ332426A NZ332426A (en) 1996-03-27 1997-03-27 Method of treating diseases involving dysfunction of ciliary movement such as ciliary dyskinesia and infertility with uridine triphosphates (UTP) and related compounds

Country Status (9)

Country Link
EP (1) EP0889728B1 (enExample)
JP (1) JP4271730B2 (enExample)
CN (1) CN1229114C (enExample)
AT (1) ATE335492T1 (enExample)
AU (1) AU727314B2 (enExample)
CA (1) CA2250188C (enExample)
DE (1) DE69736468T2 (enExample)
NZ (1) NZ332426A (enExample)
WO (1) WO1997035591A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420347B1 (en) * 1997-03-27 2002-07-16 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US6673779B2 (en) * 1996-03-27 2004-01-06 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with dinucleoside polyphosphate compounds or UTP analogues
US5968913A (en) * 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US5789391A (en) * 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6696425B2 (en) 1997-02-06 2004-02-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US6921755B2 (en) 1998-02-06 2005-07-26 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
WO1999005155A2 (en) * 1997-07-25 1999-02-04 Inspire Pharmaceuticals, Inc. Salts of di(uridine 5'-tetraphosphate), method for preparation and uses thereof
US6872710B2 (en) 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
US6420331B1 (en) 1998-06-10 2002-07-16 Procter & Gamble Company Detergent compositions comprising a mannanase and a bleach system
US6458946B1 (en) * 1998-10-02 2002-10-01 Yamasa Corporation Crystals of diuridine tetraphosphate or salt thereof, process for producing the crystals, and process for producing the compounds
US6576224B1 (en) 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
AR034635A1 (es) 2001-06-25 2004-03-03 Inspire Pharmaceuticals Inc Lubricacion de las articulaciones con agonistas del receptor purinergico p2y
JP4745608B2 (ja) 2001-07-27 2011-08-10 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 電子伝達剤のリン酸誘導体を用いた皮膚治療
TW200300692A (en) 2001-11-06 2003-06-16 Inspire Pharmaceuticals Inc Method for treating or preventing inflammatory diseases
CA2466536C (en) * 2001-12-13 2012-02-07 Vital Health Sciences Pty Ltd Transdermal transport of compounds
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
ATE495730T1 (de) 2004-03-03 2011-02-15 Vital Health Sciences Pty Ltd Alkaloid-formulierungen
EP2548581A3 (en) 2005-06-17 2013-02-20 Vital Health Sciences Pty Ltd. A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
IT1395255B1 (it) * 2009-07-09 2012-09-05 Mastelli S R L Composizione per il trattamento di infertilita' maschile
ES2999020T3 (en) 2010-02-05 2025-02-24 Phosphagenics Ltd Carrier comprising non-neutralised tocopheryl phosphate
CN102198264B (zh) * 2010-03-23 2013-10-09 中国科学院上海生命科学研究院 大鼠附睾特异抗菌肽β-防御素15及其用途
SG184181A1 (en) 2010-03-30 2012-10-30 Phosphagenics Ltd Transdermal delivery patch
WO2011161212A1 (en) * 2010-06-23 2011-12-29 P2-Science Aps Combined flow directed intraarterial microcatheter for the infusion of hyperemic agent and concomitant pressure measurements for diagnostic purposes
EP2685992A4 (en) 2011-03-15 2014-09-10 Phosphagenics Ltd AMINOCHINOLINE AS A KINASEHEMMER
CN108601732A (zh) 2015-12-09 2018-09-28 磷肌酸有限公司 药物制剂
KR102647670B1 (ko) 2016-12-21 2024-03-15 아베초 바이오테크놀로지 리미티드 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1297862A1 (ru) * 1980-07-03 1987-03-23 Институт цитологии и генетики СО АН СССР Средства дл лечени пигментной дегенерации сетчатки
EP0517573A1 (fr) * 1991-06-05 1992-12-09 Synthelabo Compositions pharmaceutiques pour le traitement des affections des voies respiratoires
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
AU7395094A (en) * 1993-10-15 1995-05-04 Wisconsin Alumni Research Foundation Substituted purine nucleoside analogs and method for treating endotoxin shock
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds

Also Published As

Publication number Publication date
CN1229114C (zh) 2005-11-30
WO1997035591B1 (en) 2001-04-26
DE69736468D1 (de) 2006-09-21
AU2594897A (en) 1997-10-17
AU727314B2 (en) 2000-12-07
EP0889728B1 (en) 2006-08-09
CA2250188A1 (en) 1997-10-02
CA2250188C (en) 2008-12-09
JP2000507557A (ja) 2000-06-20
JP4271730B2 (ja) 2009-06-03
CN1233181A (zh) 1999-10-27
WO1997035591A3 (en) 1998-01-22
EP0889728A2 (en) 1999-01-13
ATE335492T1 (de) 2006-09-15
WO1997035591A2 (en) 1997-10-02
DE69736468T2 (de) 2007-03-29

Similar Documents

Publication Publication Date Title
NZ332426A (en) Method of treating diseases involving dysfunction of ciliary movement such as ciliary dyskinesia and infertility with uridine triphosphates (UTP) and related compounds
US5763447C1 (en) Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
IL124977A0 (en) Oral administration of effective amounts of forms of hyaluronic acid
PH23867A (en) Method of treating parkinson's disease using indolone derivatives
ES2186787T3 (es) Utilizacion de ritonavir (abt-538) para mejorar la farmacocinetica de medicamentos metabolizados por el citocromo p450 en un metodo de tratamiento del sida.
DK1123094T3 (da) Terapeutiske præparater (II)
MX9709637A (es) Dinucleotidos utiles para el tratamiento de enfermedades pulmonares.
EP0962225A3 (en) Use of phentolamine for the manufacture of a medicament for the treatment of erectile dysfunction
HU213677B (en) Pharmaceutical compositions for preventing and treating tumor diseases, and process for producing them
ES2147788T3 (es) 3,4-diarilcromanos para el tratamiento de la dermatitis.
AU4488793A (en) Nadh and nadph as drugs for treating alzheimer's disease
HUP9902094A2 (hu) PGE-1-tartalmú liofilizált liposzómák erekciós zavar kezelésében való alkalmazásra
ZA9811405B (en) A method for administration of levosimendan
MY105855A (en) Therapeutic nucleotides.
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
HUP9900945A2 (hu) Nukleozidanalógok herpes simplex vírus fertőzések kombinációs terápiájában
AU2001236529A1 (en) Combination therapy for cancer
US4044122A (en) Method of treating herpes virus hominis infections
WO2000043014A3 (en) Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections
WO2025035020A3 (en) Diluted carfilzomib for use in treating multiple myeloma
WO1993007876A1 (en) Remedy for hepatic disease
Veraldi et al. Treatment of epidermolysis bullosa acquisita with cyclosporine and prednisone
RU98103823A (ru) Способ изменения свертывающей и противосвертывающей систем организма
UA30361A (uk) Спосіб лікування глікозидної інтоксикації
UA38388A (uk) Спосіб лікування епідемічного паротиту